Johnson & Johnson (NYSE:JNJ) Stock Price Expected to Rise, Argus Analyst Says

Johnson & Johnson (NYSE:JNJ) had its price target boosted by equities researchers at Argus from $240.00 to $275.00 in a research report issued on Thursday,MarketScreener reports. The brokerage presently has a “buy” rating on the stock. Argus’ target price would suggest a potential upside of 17.38% from the company’s current price.

Several other research firms also recently weighed in on JNJ. Daiwa Securities Group increased their price target on shares of Johnson & Johnson from $237.00 to $246.00 and gave the stock an “outperform” rating in a research report on Thursday. Scotiabank reissued an “outperform” rating on shares of Johnson & Johnson in a research note on Thursday, January 22nd. Barclays raised their target price on shares of Johnson & Johnson from $234.00 to $255.00 and gave the company an “equal weight” rating in a research note on Wednesday. Bank of America reaffirmed a “neutral” rating on shares of Johnson & Johnson in a research note on Monday, March 2nd. Finally, Guggenheim increased their price objective on shares of Johnson & Johnson from $240.00 to $244.00 and gave the company a “buy” rating in a research report on Tuesday, April 7th. One research analyst has rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating and nine have given a Hold rating to the company’s stock. According to data from MarketBeat.com, Johnson & Johnson has an average rating of “Moderate Buy” and an average target price of $251.52.

Johnson & Johnson Trading Down 0.1%

Shares of NYSE JNJ opened at $234.28 on Thursday. The company has a market cap of $564.29 billion, a PE ratio of 27.08, a P/E/G ratio of 2.32 and a beta of 0.34. The firm’s 50 day moving average price is $241.48 and its 200-day moving average price is $217.02. Johnson & Johnson has a 52-week low of $146.12 and a 52-week high of $251.71. The company has a debt-to-equity ratio of 0.48, a quick ratio of 0.77 and a current ratio of 1.03.

Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings data on Tuesday, April 14th. The company reported $2.70 earnings per share for the quarter, beating analysts’ consensus estimates of $2.68 by $0.02. The company had revenue of $24.06 billion for the quarter, compared to the consensus estimate of $23.60 billion. Johnson & Johnson had a net margin of 21.83% and a return on equity of 32.75%. The firm’s revenue for the quarter was up 9.9% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $2.77 earnings per share. Johnson & Johnson has set its FY 2026 guidance at 11.450-11.650 EPS. On average, equities research analysts expect that Johnson & Johnson will post 10.58 EPS for the current fiscal year.

Insider Transactions at Johnson & Johnson

In related news, EVP Timothy Schmid sold 1,322 shares of Johnson & Johnson stock in a transaction dated Friday, February 20th. The shares were sold at an average price of $245.66, for a total transaction of $324,762.52. Following the completion of the sale, the executive vice president owned 25,447 shares in the company, valued at $6,251,310.02. This trade represents a 4.94% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, EVP Vanessa Broadhurst sold 6,197 shares of Johnson & Johnson stock in a transaction dated Tuesday, February 17th. The shares were sold at an average price of $243.39, for a total transaction of $1,508,287.83. Following the sale, the executive vice president owned 23,003 shares of the company’s stock, valued at $5,598,700.17. The trade was a 21.22% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 30,142 shares of company stock valued at $7,360,528 in the last quarter. 0.16% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Johnson & Johnson

Several large investors have recently modified their holdings of the business. Demming Financial Services Corp ADV purchased a new position in shares of Johnson & Johnson in the 1st quarter worth approximately $214,000. Cidel Asset Management Inc. increased its stake in Johnson & Johnson by 10.6% during the 1st quarter. Cidel Asset Management Inc. now owns 16,123 shares of the company’s stock valued at $3,941,000 after purchasing an additional 1,540 shares in the last quarter. Bourne Lent Asset Management Inc. increased its stake in Johnson & Johnson by 1.1% during the 1st quarter. Bourne Lent Asset Management Inc. now owns 14,206 shares of the company’s stock valued at $3,473,000 after purchasing an additional 150 shares in the last quarter. Cache Advisors LLC boosted its holdings in shares of Johnson & Johnson by 61.0% in the 1st quarter. Cache Advisors LLC now owns 15,428 shares of the company’s stock valued at $3,771,000 after acquiring an additional 5,843 shares during the last quarter. Finally, Richards Merrill & Peterson Inc. boosted its holdings in shares of Johnson & Johnson by 1.2% in the 1st quarter. Richards Merrill & Peterson Inc. now owns 5,842 shares of the company’s stock valued at $1,428,000 after acquiring an additional 68 shares during the last quarter. Institutional investors own 69.55% of the company’s stock.

Trending Headlines about Johnson & Johnson

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: Barclays raised its price target to $255, citing continued pharma momentum (analyst Matt Miksic noted strong drug performance supporting upside). Barclays Raises J&J Price Target
• Positive Sentiment: Argus bumped its price target to $275 and kept a buy rating — a bullish signal that implies double‑digit upside from current levels. Argus Raises PT to $275
• Positive Sentiment: Daiwa raised its target and maintains an outperform stance, adding to the cluster of upward revisions from sell‑side shops. Daiwa Raises PT
• Positive Sentiment: Goldman Sachs and Morgan Stanley have reaffirmed buy ratings, reinforcing institutional confidence in J&J’s medium‑term growth story. Goldman Reaffirms Buy Morgan Stanley Reaffirms Buy
• Neutral Sentiment: J&J completed a transaction selling the bota‑vec asset to MeiraGTx — a portfolio pruning move that reduces R&D load but has limited near‑term earnings impact. MeiraGTx Acquires bota‑vec
• Neutral Sentiment: Multiple features highlight J&J’s dividend strength and long dividend streak, keeping income‑oriented investors engaged even as growth narratives evolve. Dividend King Coverage
• Neutral Sentiment: Roundups in The Globe and Mail note conflicting analyst views across healthcare names, underscoring mixed sell‑side positioning rather than a consensus shift. Analyst Sentiment Roundup
• Negative Sentiment: A Seeking Alpha piece lays out a bearish case, warning of valuation and operational risks that could pressure the stock if growth disappoints. Why I See Downside Ahead
• Negative Sentiment: Recent coverage revisiting J&J’s litigation headlines keeps legal overhang on the tape; this remains a key downside risk investors watch. Reassess After Litigation Headlines

Johnson & Johnson Company Profile

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.